Axplora Invests €50M in GLP-1 Manufacturing Expansion at Mourenx, France

Axplora, a German API and antibody drug conjugate (ADC) CDMO, is investing €50 million in its Mourenx site in Southwest France123.

The expansion aims to enhance GLP-1 manufacturing capabilities, focusing on therapies for diabetes and obesity125.

The investment will strengthen Axplora's position in peptide purification and support the development of next-generation biologic therapies13.

Construction and infrastructure development will begin immediately, with the first supplies of GLP-1 therapies expected in 2026125.

Axplora targets having the facility Biologics License Application (BLA)-ready in 15 months13.

The expansion will position Mourenx as a center of excellence in the Axplora network for contract manufacturing of APIs and drug substances for FDA-approved biologics1.

The investment aligns with the growing demand for GLP-1 therapies, as prescriptions for this drug type have risen by 700% in non-diabetic patients2.

Axplora specializes in large-scale API industrial chemistry and chromatography, with a focus on cardiovascular and metabolic diseases5.

The company operates nine API manufacturing sites across Europe and India, aiming to provide multi-site capacity to partners worldwide5.

This expansion is part of Axplora's strategy to support leading pharmaceutical firms while fostering innovation and regional economic growth3.

Sources:

1. https://european-biotechnology.com/latest-news/axplora-group-announces-e50m-expansion-of-glp-1-manufacturing-site/

2. https://manufacturingchemist.com/axplora-glp-1-manufacturing-expansion-mourenx-france

3. https://pharmasource.global/content/news/cdmo-news/axplora-invests-e50m-to-expand-mourenx-api-manufacturing-capabilities/

5. https://www.genengnews.com/news/axplora-invests-e50-million-in-glp-1-manufacturing-at-its-french-site/